Participated · Seed · Dec 2025

LeanCon has built what it calls the world’s first AI-enabled pre-construction engineering team, replacing the months-long bid-planning phase with a data-driven workflow that delivers cost, schedule, logistics and method projections in roughly seven minutes. By automating this historically manual process, the startup claims it can slash typical planning costs of about $2 million to virtually zero while increasing win rates and allowing firms to pursue more projects. The technology is already in use on $650 million worth of development projects in New York, providing early commercial validation. Founded by engineers Ziv Levi and Sapir Tubul, the company’s vision is to rebuild construction planning around AI so project teams can save time, cut costs and secure more bids. With fresh capital, LeanCon plans to accelerate product development and expand market adoption. No revenue figures were disclosed, but the large project pipeline underscores initial traction. The company is positioning itself to become a critical tool for contractors and developers facing tight margins and complex builds.

Participated · Series A · Aug 2024

Nob Hill Therapeutics is a respiratory-focused healthcare company developing high-dose lung delivery technologies and therapeutics. It holds a patented Dry Powder Nebulizer platform that generates drug aerosols and delivers them to the lower respiratory tract independent of patient lung capacity. The company's patent-protected inhalation device can deliver high therapeutic doses directly to the lung and is designed for patients of all ages, including those with compromised lung function. Led by CEO Noel Greenberger and based in Albuquerque, NM, NHT plans to advance its technology and therapeutics toward regulatory milestones. The company recently raised $3M in Series A financing to fund continued development of its high-dose respiratory technology and pre-IND studies. Nob Hill Therapeutics is developing a patent‑protected DryNeb dry powder nebulizer platform designed to deliver high therapeutic doses directly to the lower respiratory tract. The device is intended to be suitable for patients of all ages and inhalation capabilities and is claimed to generate highly efficient drug aerosols independent of lung capacity. The company is using the platform to develop inhaled anti‑infective therapies, including an inhaled treatment for lung fungal infection. NHT was awarded an HHS Phase II SBIR grant of up to $1.73M to fund drug powder formulation, DryNeb device development, and other pre‑IND studies. This Phase II award builds on a successful Phase I grant and encouraging animal efficacy results reported the prior year. NHT is a VIC Technology Venture Development portfolio company and recently appointed Noel Greenberger as CEO effective September 1, 2022. The company is based in Albuquerque, N.M.

Participated · Seed · Apr 2024

Pelvital USA, Inc. is a women’s health medical device company based in Eagan, Minnesota, led by President and CEO Lydia Zeller. Its first product, Flyte, is an FDA-cleared, novel in-home treatment for stress urinary incontinence (SUI) and weakened pelvic floor muscles that delivers mechanotherapy to the pelvic floor. Flyte is reported effective for mild, moderate, and severe SUI, with a typical treatment regimen of five minutes per day for six weeks. The company positions Flyte as a convenient, clinician-backed pelvic floor therapy that can be used outside clinical settings. Pelvital recently closed an additional $2.32M in a seed-plus financing to accelerate commercialization of Flyte. Pelvital, based in Eagan, MN, develops Flyte, an FDA-cleared at-home intravaginal device that delivers mechanotherapy to treat stress urinary incontinence (SUI) and strengthen pelvic floor muscles. Flyte’s mechanism pairs mechanotherapy with an active pelvic floor contraction to stimulate tissue repair and create neuromuscular memory. The device was originally developed by physicians from the Arctic University of Norway with collaborators in gynecology, muscle rehabilitation, and urinary incontinence treatment. Pelvital is led by President and CEO Lydia Zeller. The company recently closed a $2.68M seed funding round, providing capital to complete development of its next-generation product. Management plans to use the proceeds to accelerate commercialization and expand reach to clinicians and women seeking conservative, in‑home SUI treatment.

Participated · Equity · Jul 2023

PrivacyHawk provides a personal data protection service that automates removal of consumers’ personal information from tens of thousands of corporate databases and the surface web. The company says its solution reduces consumers’ risk of being in a data breach by 90% or more through automated removals. Led by CEO Aaron Mendes and CTO Justin Wright, PrivacyHawk focuses on protecting individuals from scammers, spammers, hackers, and identity thieves. The firm plans to use the new funds to improve its flagship product and to grow awareness among the broader public. The announcement frames the raise as an additional investment to support product development and marketing efforts. The company is based in Los Angeles, CA. PrivacyHawk is pioneering the personal data protection category with a comprehensive solution for managing individuals’ digital footprints. The company delivers personal data protection through robotic process automation and advanced technology to help prevent fraud, identity theft, hacks, scams and spam. Planned product enhancements include additional automation and the use of AI to identify digital-footprint vulnerabilities and optimize removal of exposures. PrivacyHawk will use the $2.7 million in funding to support growth in sales, marketing and product development. The mission-driven team of privacy advocates, big data experts and engineers focuses on protecting personal data and reducing individuals' risk of being targeted by cybercrimes. PrivacyHawk was founded in 2021 and is headquartered in Los Angeles, California.

Participated · Seed · Apr 2023

TRIO Pharmaceuticals is a biotechnology company pioneering bispecific antibodies through its proprietary TRAILBody and TIE‑ADC platforms. Its dual‑action therapies aim to directly stop tumor growth while selectively reversing tumor immunosuppression without targeting existing immune checkpoints. TRIO is advancing programs against high‑mortality cancers including multiple myeloma, acute myeloid leukemia, ovarian, endometrial, and triple‑negative breast cancer. The company positions its therapies as potent, less toxic alternatives to conventional treatments and notes its team has developed first‑in‑class FDA‑approved drugs. TRIO will use proceeds to expand preclinical activities and advance its programs toward clinical development. The financing underscores a focus on accelerating development for cancers with high unmet need. TRIO Pharmaceuticals was founded by Purdue University biophysics and structural biology alumnus Shiva Bhowmik, who serves as founder and chief operating officer. The company develops antibody-based therapeutics intended to strengthen the body’s immune response by selectively eliminating immunosuppressive cells and directly targeting cancer cells. TRIO’s approach combines removal of immunosuppressive cells with direct anticancer activity to achieve stronger antitumor immunity. The recent financing is intended to enable TRIO to advance its technology and identify the best drug candidates for further development. Company leadership expects the milestone will open opportunities for collaborations with large pharmaceutical companies and the possibility of raising future funding rounds.